Strategic Focus Position 4D Pharma as a leader in Live Biotherapeutics with a strong platform (MicroRx) and ongoing MSD collaboration to explore partnerships in oncology, CNS, autoimmune/inflammatory diseases, and vaccine-related microbiome therapies. Target pharma partners seeking novel microbiome-based drug candidates and co-development opportunities.

Clinical Pipeline Capitalize on the clinical stage assets in oncology, respiratory, and gastrointestinal areas, plus a robust pre-clinical pipeline. Use the breadth of programs to propose collaboration or out-licensing deals to sponsors looking to diversify microbiome strategies and access a biodiverse LBP portfolio.

Financial Levers Leverage the recent financing and cash runway to support partnered development, milestone-driven collaborations, and joint ventures. Highlight potential for co-funding of trials and shared risk in late-stage development with accessible financial terms given the current funding baseline.

Strategic Partnerships Target strategic collaborations and advisory relationships, including patient engagement initiatives (e.g., Parkinson’s UK) and ongoing MSD collaboration, to co-create value in patient-centric study designs, real-world evidence, and biomarker-driven programs that attract larger pharma players seeking microbiome expertise.

Operational Readiness Emphasize the scalable discovery platform and operational capabilities (MicroRx, single-strain LBPs, oral delivery) combined with a growing IP and regulatory-tailored approach to accelerate due diligence, technology transfer, and manufacturing readiness for partnered programs.